By discovering the mechanism in this signalling transduction pathway, we propose that a combined treatment of TG2 inhibition with the inhibition of key signalling targets e.g. PKCα could be more promising therapeutic approach for the treatment of S100A4 and TG2 containing tumours. The gene discussed is TGM2; the disease is neoplasm.